To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients

计划入组 100 人 · 首次发布于 2020 年 7 月 13 日

Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance

计划入组 203 人 · 首次发布于 2010 年 11 月 18 日

Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial

计划入组 30 人 · 首次发布于 2025 年 3 月 3 日

Selective orexin 1 antagonists (Sosei Heptares)

orexin 1 antagonist (anxiety)

IL-1R antagonist

Anebulo Pharmaceuticals

United States

Adial Pharmaceuticals

United States

Relmada Therapeutics

United States

TheraCryf Advances Orexin-1 Receptor Antagonist for Addiction Treatment with Korean Patent Grant and Manufacturing Milestones

Idorsia's Dual Orexin Receptor Antagonist Wins Inaugural Prix Galien Bridges Award for Insomnia Treatment Innovation

Eisai Launches DAYVIGO, First Orexin Receptor Antagonist for Insomnia Treatment in China